Assessment of Serum Omentin-1 and Interleukin-6 in the Diagnosis of Early Stages of Diabetic Nephropathy: A Cross-Sectional Observational Study

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Aug 12

PMID 39131026

Authors

Sujata Devi

Suchanda Sahu

Kishore Behera

Nibedita Priyadarshini

Debananda Sahoo

Affiliations

Soon will be listed here.

Abstract

Introduction The pathogenesis of diabetic nephropathy highlights the progression of inflammation and fibrosis from tubular to glomerular damage during the early stages of kidney involvement in diabetic individuals. As urine albumin serves as a marker for glomerular function, its detection indicates a stage of diabetic nephropathy where the glomerulus is already compromised. Consequently, relying solely on urine albumin for diagnosis becomes questionable. In our pursuit of identifying innovative biomarkers for the early detection of diabetic nephropathy, this study was crafted to explore the relationship between chemokines, omentin-1, interleukin-6, and microalbuminuria. Materials and methods Our study cohort comprised 116 patients diagnosed with diabetes mellitus. In our study, participants were stratified into two groups based on their urine albumin levels: Group 1, characterized by urine albumin creatinine ratio <30 mg/gm and estimated glomerular filtration rate >90 ml/min, and Group 2, with urine albumin creatinine ratio ≥30 mg/gm and <300 mg/gm, and estimated glomerular filtration rate >60 ml/min and <90 ml/min. Serum creatinine, glycated hemoglobin (HbA1c), fasting blood sugar and post-prandial blood sugar, lipid profile, total protein, albumin, fasting insulin, omentin-1, and interleukin-6 were estimated. Result There was a significant difference in the medians of serum urea, creatinine, omentin-1, interleukin-6, urine albumin creatinine ratio, and estimated glomerular filtration rate levels in the two groups. There was no difference in fasting blood sugar, post-prandial blood sugar, HbA1c, serum lipids, fasting insulin, and homeostatic model assessment for insulin resistance. The receiver operating characteristic curve plotted for the newer biomarkers of diabetic nephropathy showed that there was a significant diagnostic utility in diabetic nephropathy detection of serum omentin (p=0.000), interleukin-6 (p=0.002), and interleukin-6: omentin-1 ratio (p=0.000), which correlated well with the routine test that is urine microalbumin estimation. Risk assessment demonstrated that type 2 diabetes mellitus patients with an interleukin-6: omentin-1 ratio ≥0.26 had significantly higher odds, with an odds ratio of 3.97, for developing diabetic nephropathy, which was statistically significant. Conversely, a ratio of ≤0.26 was associated with kidney protection among patients with type 2 diabetes mellitus. Conclusion Our findings revealed decreased levels of omentin-1 and increased levels of interleukin-6 in the group with diabetic nephropathy compared to those without diabetic nephropathy among patients with type 2 diabetes mellitus. Interleukin-6: omentin-1 ratio of ≤0.26 was associated with kidney protection among patients with type 2 diabetes mellitus. Based on the results obtained from this study, we propose that measuring the serum interleukin-6: omentin-1 ratio in patients with type 2 diabetes mellitus may assist in identifying the early stages of diabetic nephropathy before the onset of microalbuminuria. Timely intervention in these patients predisposed to diabetic nephropathy can aid in better treatment outcomes in type 2 diabetes mellitus.

References

Osicka T, Houlihan C, Chan J, Jerums G, Comper W . Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes. 2000; 49(9):1579-84. DOI: 10.2337/diabetes.49.9.1579. View

Osicka T, Comper W . Characterization of immunochemically nonreactive urinary albumin. Clin Chem. 2004; 50(12):2286-91. DOI: 10.1373/clinchem.2004.039743. View

Unnikrishnan R, Rema M, Pradeepa R, Deepa M, Shanthirani C, Deepa R . Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diabetes Care. 2007; 30(8):2019-24. DOI: 10.2337/dc06-2554. View

Saran R, Robinson B, Abbott K, Bragg-Gresham J, Chen X, Gipson D . US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019; 75(1 Suppl 1):A6-A7. DOI: 10.1053/j.ajkd.2019.09.003. View

Burne M, Panagiotopoulos S, Jerums G, Comper W . Alterations in renal degradation of albumin in early experimental diabetes in the rat: a new factor in the mechanism of albuminuria. Clin Sci (Lond). 1998; 95(1):67-72. View

Feigerlova E, Battaglia-Hsu S . IL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017; 37:57-65. DOI: 10.1016/j.cytogfr.2017.03.003. View

Tekce H, Tekce B, Aktas G, Alcelik A, Sengul E . Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease. Exp Clin Endocrinol Diabetes. 2014; 122(8):451-6. DOI: 10.1055/s-0034-1375674. View

Sniderman A, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A . Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol. 2007; 36(1):220-5. DOI: 10.1093/ije/dyl245. View

Chen B, Wu M, Zang C, Li Y, Xu Z . Association Between IL-6 Polymorphisms and Diabetic Nephropathy Risk: A Meta-analysis. Am J Med Sci. 2019; 358(5):363-373. DOI: 10.1016/j.amjms.2019.07.011. View

10.

Bajaj M, Banerji M . Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep. 2004; 4(3):213-8. DOI: 10.1007/s11892-004-0026-4. View

11.

Agrawal L, Azad N, Bahn G, Ge L, Reaven P, Hayward R . Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2017; 61(2):295-299. PMC: 5747983. DOI: 10.1007/s00125-017-4473-2. View

12.

Senthilkumar G, Anithalekshmi M, Yasir M, Parameswaran S, Packirisamy R, Bobby Z . Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy. Diabetes Metab Syndr. 2017; 12(1):23-26. DOI: 10.1016/j.dsx.2017.08.005. View

13.

Salgado A, de Carvalho L, Oliveira A, Santos V, Vieira J, Parise E . Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010; 47(2):165-9. DOI: 10.1590/s0004-28032010000200009. View

14.

Choudhary N, Ahlawat R . Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis. 2009; 2(2):72-9. View

15.

Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S . Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020; 162:108072. DOI: 10.1016/j.diabres.2020.108072. View

16.

Watanabe T, Watanabe-Kominato K, Takahashi Y, Kojima M, Watanabe R . Adipose Tissue-Derived Omentin-1 Function and Regulation. Compr Physiol. 2017; 7(3):765-781. DOI: 10.1002/cphy.c160043. View

17.

Van J, Scholey J, Konvalinka A . Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics. J Am Soc Nephrol. 2017; 28(4):1050-1061. PMC: 5373465. DOI: 10.1681/ASN.2016091018. View

18.

McCarty M . Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses. 1999; 52(5):465-77. DOI: 10.1054/mehy.1997.0684. View

19.

Lesna J, Ticha A, Hyspler R, Musil F, Blaha V, Sobotka L . Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutr Diabetes. 2015; 5:e183. PMC: 4631935. DOI: 10.1038/nutd.2015.33. View

20.

Shikano M, Sobajima H, Yoshikawa H, Toba T, Kushimoto H, Katsumata H . Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron. 2000; 85(1):81-5. DOI: 10.1159/000045634. View